patent-istock-579425600-duncan-andison
Duncan_Andison / iStockphoto.com
7 March 2017Americas

PTAB denies Celltrion’s patent challenge against Genentech

The Patent Trial and Appeal Board (PTAB) has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
31 October 2017   The Patent Trial and Appeal Board has agreed to rehear an inter partes review (IPR) filed by Hospira, a company now owned by Pfizer.

More on this story

Americas
31 October 2017   The Patent Trial and Appeal Board has agreed to rehear an inter partes review (IPR) filed by Hospira, a company now owned by Pfizer.

More on this story

Americas
31 October 2017   The Patent Trial and Appeal Board has agreed to rehear an inter partes review (IPR) filed by Hospira, a company now owned by Pfizer.